NASDAQ: KOD · Life Sciences · 8 alerts · CIK 1468748
Share price
$100.73Close, Nov 16
Market cap
$6.59B
Shares outstanding
65.4MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Kodiak Sciences Inc. filings on SEC EDGAR ↗
Kodiak Sciences Inc. reported a net loss of $190.0 million for the first nine months of 2026, compared to $173.2 million in the prior year period, driven primarily by increased research and development expenses. The company's cash position decreased significantly to $88.7 million as of September 30, 2026, and management indicated a need to raise additional capital to maintain operations and continue its clinical development programs.
Kodiak Sciences reported Q3 2026 financial results and provided updates on its late-stage retinal pipeline, including positive Phase 3 DAYBREAK results for Zenkuda and tabirafusp-ted. The company plans to submit a multi-indication BLA for Zenkuda by the end of 2026 and expects pivotal data for KSI-101 in December 2026.
“We believe Kodiak stands apart in retina, with three late-stage assets that together give us the opportunity to build a leading retinal medicines company.”
Victor Perlroth, M.D., Chief Executive Officer of Kodiak Sciences
“Looking ahead, we expect to announce the first Phase 3 KSI-101 results in December and, if successful, plan to file a BLA for KSI-101 in the second quarter of 2027. We are also on track to submit the multi-indication BLA for Zenkuda by year end, supported by five successful Phase 3 studies.”
Victor Perlroth, M.D., Chief Executive Officer of Kodiak Sciences